Lehrstuhl für Geburtshilfe und Frauenheilkunde

The DETECT Study Concept - Metastatic breast cancer and circulating tumor cells (2016) Schramm A, Friedl T, Rack B, Trapp E, Fasching P, Taran FA, Hartkopf A, et al. Conference contribution Targeted Intraoperative Radiation Therapy Tumor Bed Boost During Breast-Conserving Surgery After Neoadjuvant Chemotherapy in TNBC and HER2 Positive Breast Cancer (2016) Kolberg HC, Loevey G, Akpolat-Basci L, Stephanou M, Fasching P, Untch M, Liedtke C, et al. Conference contribution Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial (2016) Janning M, Mueller , Vettorazzi E, Cubas-Cordova M, Gensch , Ben Batalla , Eulenburg ZC, et al. Conference contribution Short Report on the Commission Work Financing Commission - successful work continues! (2016) Renner S, Wallwiener D, Beckmann M Journal article Single Deepest Vertical Pocket or Amniotic Fluid Index as Evaluation Test for Predicting Adverse Pregnancy Outcome (SAFE Trial): A Multicenter, Open-Label, Randomized Controlled Trial EDITORIAL COMMENT (2016) Kehl S, Schelkle A, Thomas A, Puhl A, Meqdad K, Tuschy B, Berlit S, et al. Journal article, Editorial Tumor-infiltrating lymphocytes and response prediction to neoadjuvant chemotherapy in HER2-positive breast cancer (2016) Heppner BI, Untch M, Denkert C, Pfitzner BM, Lederer B, Schmidt W, Eidtmann H, et al. Conference contribution KNOCK-OUT OF THE HUMAN ENDOGENOUS RETROVIRUS ERV3 USING CRISPR/CAS9 TECHNOLOGY (2016) Hübner H, Fahlbusch FB, Ekici AB, Vasileiou G, Beckmann M, Strick R, Rübner M Conference contribution Psychooncological counseling and treatment as part of the Comprehensive Cancer Center (CCC): Multicenter study to detect the psycho-oncological needs, indications and using (2016) Buettner-Teleaga A, Weis J, Goerling U, Hornemann B, Erim Y, Beckmann M, Senf B, et al. Conference contribution Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple negative or luminal B/HER2 normal breast cancer (GENEVIEVE) (2016) Paepke S, Huober J, Sherko K, Eidtmann H, Untch M, Costa SD, Blohmer JU, et al. Conference contribution Erratum to: The integrative epigenomic-transcriptomic landscape of ER positive breast cancer (2016) Gao Y, Jones A, Fasching P, Rübner M, Beckmann M, Widschwendter M, Teschendorff AE Journal article